Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently recognized as a systemic disorder inducing a prothrombotic state. The molecular mechanisms underlying the hypercoagulable state seen in patients with COVID-19 is still incompletely understood, although it presumably involves the close link between inflammatory and hemostatic systems. The laboratory coagulation monitoring of severely ill COVID-19 patients is mandatory to identify those patients at increased thrombotic risk and to modulate thromboprophylaxis accordingly. In this review, we summarize the current understanding on the pathogenesis, epidemiology, clinical and laboratory features and management of coagulopathy associated with COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1515/dx-2020-0078 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Retrospective Analysis of Thrombosis and COVID-19 Mortality in Rural Midwestern Population.
Cureus
November 2024
College of Osteopathic Medicine, Kansas City University of Medicine and Biosciences, Joplin, USA.
Background COVID-19 disease has caused a major global impact on health and mortality. This infection may predispose patients to thrombotic disease, caused by excessive inflammation, endothelial dysfunction, platelet activation, and stasis. In this study, we compared mortality rates in patients admitted to the hospital with the diagnosis of COVID-19, who also had the additional diagnosis of thrombosis with those who did not have thrombosis as an additional diagnosis.
View Article and Find Full Text PDFProthrombotic state and thrombotic events in COVID-19 pandemic period, including portal vein and splenic artery thromboses.
World J Clin Cases
November 2024
Department of Emergency Medicine, Istanbul Aydin University, Istanbul 34295, Kucukcekmece, Istanbul, Türkiye.
This editorial article is intended to perform a discussion on the manuscript entitled "Simultaneous portal vein thrombosis and splenic vein thrombosis in a COVID-19 patient: A case report and review of literature" written by Abramowitz . The article focuses on the diagnostic processes in a 77-year-old-male patient with a simultaneous portal vein and splenic artery thrombosis accompanying coronavirus disease 2019 (COVID-19). The authors postulated that splanchnic thrombosis should be on the list of differential diagnoses in a patient presenting with abdominal pain in presence of a COVID-19 infection.
View Article and Find Full Text PDFCoronavirus Disease 2019-Associated Thrombotic Microangiopathy: A Single-Center Experience.
Int J Mol Sci
November 2024
Department of Nephrology, University Medical Center Ljubljana, 1000 Ljubljana, Slovenia.
Article Synopsis
- COVID-19 can lead to multiorgan issues, including thrombotic microangiopathy (TMA), which we studied in eight patients at our center.
- Most patients showed few COVID-19 symptoms, and TMA occurred after the virus was present in their system; two had additional non-COVID-related factors triggering TMA.
- Treatments varied based on the type of TMA, with some achieving recovery in blood and kidney functions, highlighting the need for tailored treatment approaches due to different causes and responses.
Investigation of ADAMTS-13 levels in patients with COVID-19 infection.
J Infect Dev Ctries
September 2024
Department of Pediatric Hematology and Oncology, Faculty of Medicine, Usak University, Usak, Turkiye.
Article Synopsis
- COVID-19 patients have a higher risk of blood clotting issues, possibly linked to ADAMTS-13 levels, a protein that helps regulate blood clotting.
- A study on 180 patients categorized them into mild and severe COVID-19 groups, comparing their ADAMTS-13 levels with a control group, using various clinical tests.
- Results showed no significant differences in ADAMTS-13 levels between the groups, suggesting that it may not be a reliable biomarker for assessing patient risk upon admission.
Trends in COVID-19-Attributable Hospitalizations Among Adults With Laboratory-Confirmed SARS-CoV-2-COVID-NET, June 2020 to September 2023.
Influenza Other Respir Viruses
November 2024
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Article Synopsis
- * An analysis of 44,816 hospitalizations revealed that 90% of cases were likely attributable to COVID-19, particularly focusing on admissions from July 2022 to September 2023, where 86% were linked to COVID-19-related symptoms and treatments.
- * The research found that younger adults and those without underlying health conditions were less likely to have COVID-19-attributable hospitalizations, suggesting that severe cases are more prevalent in older patients and those with pre-existing health issues.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!